Avanir Pharmaceuticals - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsAvanir Pharmaceuticals

Avanir Pharmaceuticals(AVNR)

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

*Currency in USD

Company Revenue

No data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Nuedexta	Dextromethorphan, Quinidine	2010-10-29	2023-2040	Atrial fibrillation , Atrial flutter , Cardiac arrhythmias , Cough , Neurobehavioral manifestations , Sinusitis , Asthma , Common cold , Allergic rhinitis perennial , Urticaria , Vasomotor rhinitis , Whooping cough , Bronchitis , Pharyngitis , Laryngitis , Postoperative complications , Pain , Vomiting , Nausea , Anaphylaxis , Allergic conjunctivitis , Motion sickness , Tobacco use disorder , Attention deficit disorder with hyperactivity , Depressive disorder

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

Dextromethorphan

tobacco use disorder

,

cigarette smoking

,

smoking cessation

,

alzheimer disease

,

,

psychomotor agitation

,

treatment-resistant depressive disorder

,

,

major depressive disorder

,

depressive disorder

,

Quinidine gluconate

healthy volunteers/patients

,

major depressive disorder

,

depressive disorder

Quinidine polygalacturonate

healthy volunteers/patients

,

major depressive disorder

,

depressive disorder

healthy volunteers/patients

,

major depressive disorder

,

depressive disorder

,

diabetic neuropathies

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use